title: Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival.
abstract: Recent evidence links aberrant activation of Hedgehog (Hh) signaling with the pathogenesis of several cancers including medulloblastoma, glioblastoma, melanoma as well as pancreas, colorectal, and prostate carcinomas. Here we investigated the role of the transcription factor Gli1 in ovarian cancer. To this end, the expression profile of Gli1 was examined in normal ovaries, ovarian tumors, and ovarian cancer cell lines, and the in vitro effects of a specific Hh-pathway blocker, KAAD-cyclopamine, or a specific Gli1 inhibitor (GANT58) on cell proliferation and on Hh target gene expression were also assessed. Results obtained showed that epithelial cells in ovarian cancer tissue express significantly higher levels of nuclear Gli1 than in normal ovarian tissue, where the protein was almost undetectable. In addition, multivariate analysis showed that nuclear Gli1 was independently associated to poor survival in advanced serous ovarian cancer patients (HR = 2.2, 95%CI 1.0-5.1, p = 0.04). In vitro experiments demonstrated Gli1 expression in the three ovarian carcinoma cell lines tested, A2780, SKOV-3 and OVCAR-3. Remarkably, although KAAD-cyclopamine led to decreased cell proliferation, this treatment did not inhibit hedgehog target gene expression in any of the three ovarian cancer cell lines, suggesting that the inhibition of cell proliferation was a nonspecific or toxic effect. In line with these data, no differences on cell proliferation were observed when cell lines were treated with GANT58. Overall, our clinical data support the role of Gli1 as a prognostic marker in advanced serous ovarian cancer and as a possible therapeutic target in this disease. However, our in vitro findings draw attention to the need for selection of appropriate experimental models that accurately represent human tumor for testing future therapies involving Hh pathway inhibitors.
authors.affiliation: Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ciucci
authors.forename: Ilaria
authors.initials: I
authors.lastname: De Stefano
authors.forename: Valerio Gaetano
authors.initials: VG
authors.lastname: Vellone
authors.forename: Lucia
authors.initials: L
authors.lastname: Lisi
authors.forename: Carolina
authors.initials: C
authors.lastname: Bottoni
authors.forename: Giovanni
authors.initials: G
authors.lastname: Scambia
authors.forename: Gian Franco
authors.initials: GF
authors.lastname: Zannoni
authors.forename: Daniela
authors.initials: D
authors.lastname: Gallo
mesh_terms: D000328:Adult; D000368:Aged; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002934:Cinnamates / Q000494:pharmacology; D005260:Female; D006801:Humans; D047468:Immunoprecipitation; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D060888:Real-Time Polymerase Chain Reaction; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D014704:Veratrum Alkaloids / Q000494:pharmacology; D000071676:Zinc Finger Protein GLI1
chemical_list: C542465:3-keto-N-aminoethylaminoethylcaproyldihydrocinnamoyl cyclopamine; D002934:Cinnamates; C400551:GLI1 protein, human; D014157:Transcription Factors; D014704:Veratrum Alkaloids; D000071676:Zinc Finger Protein GLI1
references.citation: Nat Cell Biol. 2006 Dec;8(12):1415-23
references.pmid: 17115028
references.citation: Cancer Sci. 2007 Jan;98(1):68-76
references.pmid: 17083567
references.citation: Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60
references.pmid: 17494766
references.citation: J Natl Cancer Inst. 2004 Mar 17;96(6):487-8
references.pmid: 15026475
references.citation: PLoS One. 2010 Apr 16;5(4):e10202
references.pmid: 20419137
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Development. 1998 Sep;125(18):3553-62
references.pmid: 9716521
references.citation: Exp Cell Res. 2012 Oct 1;318(16):1959-72
references.pmid: 22659135
references.citation: Mol Cancer. 2009 Nov 27;8:112
references.pmid: 19943941
references.citation: Curr Drug Targets. 2010 Apr;11(4):474-81
references.pmid: 20015012
references.citation: Clin Cancer Res. 2012 Dec 1;18(23):6509-18
references.pmid: 23032746
references.citation: Eur J Clin Chem Clin Biochem. 1995 Nov;33(11):813-23
references.pmid: 8620058
references.citation: Mol Cancer Ther. 2012 Jul;11(7):1587-97
references.pmid: 22553355
references.citation: Nature. 2000 Aug 31;406(6799):1005-9
references.pmid: 10984056
references.citation: Clin Cancer Res. 2012 Sep 15;18(18):4883-8
references.pmid: 22718857
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4646-56
references.pmid: 22733539
references.citation: Carcinogenesis. 2009 Jan;30(1):131-40
references.pmid: 19028702
references.citation: Genes Dev. 2002 Nov 1;16(21):2743-8
references.pmid: 12414725
references.citation: Curr Oncol. 2007 Oct;14(5):195-208
references.pmid: 17938703
references.citation: J Neurooncol. 2011 Jul;103(3):459-67
references.pmid: 20953661
references.citation: EMBO J. 2009 Mar 18;28(6):663-76
references.pmid: 19214186
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7659-66
references.pmid: 19047091
references.citation: Biochem Pharmacol. 2012 Dec 1;84(11):1409-18
references.pmid: 22964220
references.citation: Clin Cancer Res. 2010 Jun 15;16(12):3130-40
references.pmid: 20530699
references.citation: J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s
references.pmid: 12743133
references.citation: Cancer. 2009 Mar 15;115(6):1234-44
references.pmid: 19189349
references.citation: J Biol Chem. 2012 Aug 17;287(34):28745-54
references.pmid: 22773833
references.citation: Gynecol Oncol. 2011 Sep;122(3):573-9
references.pmid: 21665249
references.citation: Nature. 2008 Sep 18;455(7211):406-10
references.pmid: 18754008
references.citation: BMC Cancer. 2009 Aug 25;9:298
references.pmid: 19706168
references.citation: Biochim Biophys Acta. 2010 Apr;1805(2):181-208
references.pmid: 20085802
references.citation: J Urol. 2007 Mar;177(3):832-8
references.pmid: 17296352
references.citation: N Engl J Med. 2004 Dec 9;351(24):2519-29
references.pmid: 15590954
references.citation: Oncogene. 2007 Feb 22;26(8):1122-36
references.pmid: 16964293
references.citation: Oncogene. 2012 Nov 1;31(44):4718-24
references.pmid: 22266871
references.citation: Trends Cell Biol. 2007 Sep;17(9):438-47
references.pmid: 17845852
references.citation: Br J Cancer. 1989 Oct;60(4):523-8
references.pmid: 2529890
references.citation: Cancer Sci. 2011 Oct;102(10):1756-60
references.pmid: 21679342
references.citation: J Mol Cell Biol. 2010 Apr;2(2):84-95
references.pmid: 20083481